nodes	percent_of_prediction	percent_of_DWPC	metapath
Alprostadil—Peritonitis—Riluzole—amyotrophic lateral sclerosis	0.0472	0.0631	CcSEcCtD
Alprostadil—Disseminated intravascular coagulation—Riluzole—amyotrophic lateral sclerosis	0.0334	0.0447	CcSEcCtD
Alprostadil—Stiffness—Riluzole—amyotrophic lateral sclerosis	0.0314	0.042	CcSEcCtD
Alprostadil—Hypochromic anaemia—Riluzole—amyotrophic lateral sclerosis	0.0308	0.0411	CcSEcCtD
Alprostadil—Priapism—Riluzole—amyotrophic lateral sclerosis	0.0247	0.033	CcSEcCtD
Alprostadil—Peripheral vascular disorder—Riluzole—amyotrophic lateral sclerosis	0.0243	0.0325	CcSEcCtD
Alprostadil—Pneumothorax—Riluzole—amyotrophic lateral sclerosis	0.024	0.0321	CcSEcCtD
Alprostadil—Cerebral haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.0216	0.0288	CcSEcCtD
Alprostadil—Body temperature decreased—Riluzole—amyotrophic lateral sclerosis	0.0213	0.0285	CcSEcCtD
Alprostadil—Hypothermia—Riluzole—amyotrophic lateral sclerosis	0.0213	0.0285	CcSEcCtD
Alprostadil—Micturition urgency—Riluzole—amyotrophic lateral sclerosis	0.021	0.0281	CcSEcCtD
Alprostadil—Respiratory distress—Riluzole—amyotrophic lateral sclerosis	0.0188	0.0251	CcSEcCtD
Alprostadil—Supraventricular tachycardia—Riluzole—amyotrophic lateral sclerosis	0.0182	0.0243	CcSEcCtD
Alprostadil—Pulmonary function test decreased—Riluzole—amyotrophic lateral sclerosis	0.0158	0.0212	CcSEcCtD
Alprostadil—Respiratory depression—Riluzole—amyotrophic lateral sclerosis	0.0158	0.0212	CcSEcCtD
Alprostadil—Ventricular fibrillation—Riluzole—amyotrophic lateral sclerosis	0.0156	0.0208	CcSEcCtD
Alprostadil—PTGIR—hindbrain—amyotrophic lateral sclerosis	0.0154	0.115	CbGeAlD
Alprostadil—Apnoea—Riluzole—amyotrophic lateral sclerosis	0.0141	0.0188	CcSEcCtD
Alprostadil—Accidental injury—Riluzole—amyotrophic lateral sclerosis	0.0135	0.018	CcSEcCtD
Alprostadil—Musculoskeletal stiffness—Riluzole—amyotrophic lateral sclerosis	0.0133	0.0178	CcSEcCtD
Alprostadil—Hypercholesterolaemia—Riluzole—amyotrophic lateral sclerosis	0.0126	0.0169	CcSEcCtD
Alprostadil—Injection site reaction—Riluzole—amyotrophic lateral sclerosis	0.0119	0.0159	CcSEcCtD
Alprostadil—Cramps of lower extremities—Riluzole—amyotrophic lateral sclerosis	0.011	0.0147	CcSEcCtD
Alprostadil—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.0108	0.0144	CcSEcCtD
Alprostadil—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.0104	0.0138	CcSEcCtD
Alprostadil—Diabetes mellitus—Riluzole—amyotrophic lateral sclerosis	0.00996	0.0133	CcSEcCtD
Alprostadil—Cardiac failure congestive—Riluzole—amyotrophic lateral sclerosis	0.00955	0.0128	CcSEcCtD
Alprostadil—Injury—Riluzole—amyotrophic lateral sclerosis	0.00942	0.0126	CcSEcCtD
Alprostadil—PTGIR—brainstem—amyotrophic lateral sclerosis	0.00883	0.066	CbGeAlD
Alprostadil—PTGIR—Endothelin Pathways—ECE1—amyotrophic lateral sclerosis	0.0087	0.0743	CbGpPWpGaD
Alprostadil—Cardiac arrest—Riluzole—amyotrophic lateral sclerosis	0.00824	0.011	CcSEcCtD
Alprostadil—Hypokalaemia—Riluzole—amyotrophic lateral sclerosis	0.00788	0.0105	CcSEcCtD
Alprostadil—PTGER1—nervous system—amyotrophic lateral sclerosis	0.00749	0.056	CbGeAlD
Alprostadil—Influenza—Riluzole—amyotrophic lateral sclerosis	0.00749	0.01	CcSEcCtD
Alprostadil—PTGER1—central nervous system—amyotrophic lateral sclerosis	0.00721	0.0539	CbGeAlD
Alprostadil—Bronchitis—Riluzole—amyotrophic lateral sclerosis	0.0072	0.00962	CcSEcCtD
Alprostadil—Pollakiuria—Riluzole—amyotrophic lateral sclerosis	0.00692	0.00924	CcSEcCtD
Alprostadil—Acute coronary syndrome—Riluzole—amyotrophic lateral sclerosis	0.00658	0.00879	CcSEcCtD
Alprostadil—Myocardial infarction—Riluzole—amyotrophic lateral sclerosis	0.00654	0.00875	CcSEcCtD
Alprostadil—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.00649	0.00867	CcSEcCtD
Alprostadil—Haematuria—Riluzole—amyotrophic lateral sclerosis	0.00636	0.00851	CcSEcCtD
Alprostadil—Sinusitis—Riluzole—amyotrophic lateral sclerosis	0.00626	0.00837	CcSEcCtD
Alprostadil—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.0061	0.00815	CcSEcCtD
Alprostadil—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.00602	0.00805	CcSEcCtD
Alprostadil—Rhinitis—Riluzole—amyotrophic lateral sclerosis	0.00601	0.00803	CcSEcCtD
Alprostadil—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.00599	0.00801	CcSEcCtD
Alprostadil—Hypoaesthesia—Riluzole—amyotrophic lateral sclerosis	0.00596	0.00797	CcSEcCtD
Alprostadil—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.00595	0.00795	CcSEcCtD
Alprostadil—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.00587	0.00785	CcSEcCtD
Alprostadil—PTGIR—spinal cord—amyotrophic lateral sclerosis	0.00549	0.041	CbGeAlD
Alprostadil—SLCO3A1—medulla oblongata—amyotrophic lateral sclerosis	0.00544	0.0406	CbGeAlD
Alprostadil—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00507	0.00677	CcSEcCtD
Alprostadil—Back pain—Riluzole—amyotrophic lateral sclerosis	0.00505	0.00674	CcSEcCtD
Alprostadil—Muscle spasms—Riluzole—amyotrophic lateral sclerosis	0.00502	0.0067	CcSEcCtD
Alprostadil—ABCC5—medulla oblongata—amyotrophic lateral sclerosis	0.00492	0.0368	CbGeAlD
Alprostadil—SLCO3A1—spinal cord—amyotrophic lateral sclerosis	0.00485	0.0362	CbGeAlD
Alprostadil—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.00482	0.00644	CcSEcCtD
Alprostadil—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00468	0.00625	CcSEcCtD
Alprostadil—PTGIR—nervous system—amyotrophic lateral sclerosis	0.00463	0.0346	CbGeAlD
Alprostadil—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.00459	0.00613	CcSEcCtD
Alprostadil—Cough—Riluzole—amyotrophic lateral sclerosis	0.00455	0.00608	CcSEcCtD
Alprostadil—Convulsion—Riluzole—amyotrophic lateral sclerosis	0.00452	0.00604	CcSEcCtD
Alprostadil—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.0045	0.00602	CcSEcCtD
Alprostadil—PTGIR—central nervous system—amyotrophic lateral sclerosis	0.00446	0.0333	CbGeAlD
Alprostadil—PTGER2—Prostaglandin Synthesis and Regulation—PLA2G4A—amyotrophic lateral sclerosis	0.00443	0.0378	CbGpPWpGaD
Alprostadil—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00439	0.00586	CcSEcCtD
Alprostadil—PTGIR—cerebellum—amyotrophic lateral sclerosis	0.00435	0.0325	CbGeAlD
Alprostadil—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00434	0.00581	CcSEcCtD
Alprostadil—Oedema—Riluzole—amyotrophic lateral sclerosis	0.00426	0.00569	CcSEcCtD
Alprostadil—Infection—Riluzole—amyotrophic lateral sclerosis	0.00423	0.00565	CcSEcCtD
Alprostadil—Shock—Riluzole—amyotrophic lateral sclerosis	0.00419	0.0056	CcSEcCtD
Alprostadil—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00417	0.00557	CcSEcCtD
Alprostadil—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00416	0.00555	CcSEcCtD
Alprostadil—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.00414	0.00553	CcSEcCtD
Alprostadil—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00412	0.0055	CcSEcCtD
Alprostadil—SLCO3A1—nervous system—amyotrophic lateral sclerosis	0.00408	0.0305	CbGeAlD
Alprostadil—SLCO2A1—nervous system—amyotrophic lateral sclerosis	0.00404	0.0302	CbGeAlD
Alprostadil—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00398	0.00532	CcSEcCtD
Alprostadil—SLCO3A1—central nervous system—amyotrophic lateral sclerosis	0.00393	0.0294	CbGeAlD
Alprostadil—SLCO2A1—central nervous system—amyotrophic lateral sclerosis	0.00389	0.0291	CbGeAlD
Alprostadil—SLCO2B1—medulla oblongata—amyotrophic lateral sclerosis	0.00385	0.0288	CbGeAlD
Alprostadil—SLCO3A1—cerebellum—amyotrophic lateral sclerosis	0.00384	0.0287	CbGeAlD
Alprostadil—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00375	0.00501	CcSEcCtD
Alprostadil—Pain—Riluzole—amyotrophic lateral sclerosis	0.00364	0.00487	CcSEcCtD
Alprostadil—PTGIR—brain—amyotrophic lateral sclerosis	0.00354	0.0264	CbGeAlD
Alprostadil—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00351	0.00469	CcSEcCtD
Alprostadil—ABCC5—cerebellum—amyotrophic lateral sclerosis	0.00348	0.026	CbGeAlD
Alprostadil—SLCO2B1—spinal cord—amyotrophic lateral sclerosis	0.00344	0.0257	CbGeAlD
Alprostadil—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00337	0.0045	CcSEcCtD
Alprostadil—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.00337	0.0045	CcSEcCtD
Alprostadil—SLCO3A1—brain—amyotrophic lateral sclerosis	0.00312	0.0233	CbGeAlD
Alprostadil—SLCO2A1—brain—amyotrophic lateral sclerosis	0.00309	0.0231	CbGeAlD
Alprostadil—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00305	0.00408	CcSEcCtD
Alprostadil—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00301	0.00403	CcSEcCtD
Alprostadil—PTGER1—Prostaglandin Synthesis and Regulation—PLA2G4A—amyotrophic lateral sclerosis	0.00299	0.0255	CbGpPWpGaD
Alprostadil—PTGIR—Prostaglandin Synthesis and Regulation—PLA2G4A—amyotrophic lateral sclerosis	0.00299	0.0255	CbGpPWpGaD
Alprostadil—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00291	0.00389	CcSEcCtD
Alprostadil—SLCO2B1—nervous system—amyotrophic lateral sclerosis	0.0029	0.0216	CbGeAlD
Alprostadil—ABCC5—brain—amyotrophic lateral sclerosis	0.00283	0.0211	CbGeAlD
Alprostadil—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.00282	0.00376	CcSEcCtD
Alprostadil—SLCO2B1—central nervous system—amyotrophic lateral sclerosis	0.00279	0.0208	CbGeAlD
Alprostadil—SLCO2B1—cerebellum—amyotrophic lateral sclerosis	0.00272	0.0204	CbGeAlD
Alprostadil—Rash—Riluzole—amyotrophic lateral sclerosis	0.00268	0.00359	CcSEcCtD
Alprostadil—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00268	0.00358	CcSEcCtD
Alprostadil—Headache—Riluzole—amyotrophic lateral sclerosis	0.00267	0.00356	CcSEcCtD
Alprostadil—ABCC4—nervous system—amyotrophic lateral sclerosis	0.00256	0.0192	CbGeAlD
Alprostadil—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00253	0.00338	CcSEcCtD
Alprostadil—PTGER2—Prostaglandin Synthesis and Regulation—PTGS2—amyotrophic lateral sclerosis	0.0025	0.0213	CbGpPWpGaD
Alprostadil—ABCC4—central nervous system—amyotrophic lateral sclerosis	0.00247	0.0184	CbGeAlD
Alprostadil—SLCO2B1—brain—amyotrophic lateral sclerosis	0.00221	0.0165	CbGeAlD
Alprostadil—ABCC4—Platelet degranulation—TUBA4A—amyotrophic lateral sclerosis	0.00208	0.0178	CbGpPWpGaD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.00207	0.0177	CbGpPWpGaD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—TUBA4A—amyotrophic lateral sclerosis	0.00198	0.0169	CbGpPWpGaD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.00196	0.0168	CbGpPWpGaD
Alprostadil—ABCC4—brain—amyotrophic lateral sclerosis	0.00196	0.0146	CbGeAlD
Alprostadil—ABCC4—Platelet degranulation—PFN1—amyotrophic lateral sclerosis	0.00188	0.016	CbGpPWpGaD
Alprostadil—ABCC5—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00179	0.0153	CbGpPWpGaD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—PFN1—amyotrophic lateral sclerosis	0.00179	0.0153	CbGpPWpGaD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.00176	0.015	CbGpPWpGaD
Alprostadil—PTGIR—Prostaglandin Synthesis and Regulation—PTGS2—amyotrophic lateral sclerosis	0.00169	0.0144	CbGpPWpGaD
Alprostadil—PTGER1—Prostaglandin Synthesis and Regulation—PTGS2—amyotrophic lateral sclerosis	0.00169	0.0144	CbGpPWpGaD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.00167	0.0143	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.00163	0.0139	CbGpPWpGaD
Alprostadil—SLCO2A1—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.00157	0.0134	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.00155	0.0132	CbGpPWpGaD
Alprostadil—SLCO3A1—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.00149	0.0127	CbGpPWpGaD
Alprostadil—PTGIR—Platelet homeostasis—PLA2G4A—amyotrophic lateral sclerosis	0.00139	0.0119	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.00137	0.0117	CbGpPWpGaD
Alprostadil—ABCC5—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.00131	0.0112	CbGpPWpGaD
Alprostadil—ABCC4—NRF2 pathway—GSR—amyotrophic lateral sclerosis	0.00124	0.0106	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.00115	0.00984	CbGpPWpGaD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.00114	0.00972	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.00105	0.00899	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.00105	0.00893	CbGpPWpGaD
Alprostadil—ABCC5—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.00101	0.00861	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000998	0.00852	CbGpPWpGaD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000968	0.00827	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000927	0.00792	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—C5AR1—amyotrophic lateral sclerosis	0.000927	0.00792	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—TUBA4A—amyotrophic lateral sclerosis	0.000924	0.00789	CbGpPWpGaD
Alprostadil—ABCC4—NRF2 pathway—SLC6A1—amyotrophic lateral sclerosis	0.000907	0.00774	CbGpPWpGaD
Alprostadil—ABCC4—Platelet degranulation—SOD1—amyotrophic lateral sclerosis	0.000907	0.00774	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000898	0.00767	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000895	0.00764	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000895	0.00764	CbGpPWpGaD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—SOD1—amyotrophic lateral sclerosis	0.000864	0.00738	CbGpPWpGaD
Alprostadil—SLCO2B1—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000863	0.00737	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000858	0.00733	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000848	0.00724	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000848	0.00724	CbGpPWpGaD
Alprostadil—Dihomo-gamma-linolenic acid—PTGS2—amyotrophic lateral sclerosis	0.000842	1	CrCbGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—PFN1—amyotrophic lateral sclerosis	0.000832	0.0071	CbGpPWpGaD
Alprostadil—ABCC5—Fluoropyrimidine Activity—TP53—amyotrophic lateral sclerosis	0.000799	0.00683	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.000799	0.00682	CbGpPWpGaD
Alprostadil—SLCO2A1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000798	0.00681	CbGpPWpGaD
Alprostadil—ABCC5—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000789	0.00674	CbGpPWpGaD
Alprostadil—SLCO3A1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000756	0.00646	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.000743	0.00634	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.000719	0.00614	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000706	0.00603	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—C5AR1—amyotrophic lateral sclerosis	0.000706	0.00603	CbGpPWpGaD
Alprostadil—ABCC4—NRF2 pathway—SQSTM1—amyotrophic lateral sclerosis	0.000699	0.00597	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—KIFAP3—amyotrophic lateral sclerosis	0.000687	0.00587	CbGpPWpGaD
Alprostadil—ABCC5—Disease—TPK1—amyotrophic lateral sclerosis	0.000633	0.00541	CbGpPWpGaD
Alprostadil—PTGER2—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000599	0.00512	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000595	0.00508	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000591	0.00505	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000579	0.00494	CbGpPWpGaD
Alprostadil—ABCC4—Fluoropyrimidine Activity—TP53—amyotrophic lateral sclerosis	0.000554	0.00473	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000553	0.00472	CbGpPWpGaD
Alprostadil—ABCC4—Platelet degranulation—IGF1—amyotrophic lateral sclerosis	0.000553	0.00472	CbGpPWpGaD
Alprostadil—ABCC4—NRF2 pathway—GSTP1—amyotrophic lateral sclerosis	0.000547	0.00467	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000537	0.00458	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—VAPB—amyotrophic lateral sclerosis	0.00053	0.00453	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—TPK1—amyotrophic lateral sclerosis	0.00053	0.00453	CbGpPWpGaD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—IGF1—amyotrophic lateral sclerosis	0.000527	0.0045	CbGpPWpGaD
Alprostadil—ABCC5—Disease—VTA1—amyotrophic lateral sclerosis	0.000506	0.00432	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000492	0.0042	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000492	0.0042	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000485	0.00414	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TUBA4A—amyotrophic lateral sclerosis	0.000476	0.00407	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.00047	0.00401	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.00047	0.00401	CbGpPWpGaD
Alprostadil—PTGER2—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000456	0.0039	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000451	0.00385	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—RAB5A—amyotrophic lateral sclerosis	0.000443	0.00378	CbGpPWpGaD
Alprostadil—SLCO2B1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000438	0.00374	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PFN1—amyotrophic lateral sclerosis	0.000429	0.00366	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000424	0.00362	CbGpPWpGaD
Alprostadil—ABCC5—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.000419	0.00358	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000418	0.00357	CbGpPWpGaD
Alprostadil—PTGIR—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000405	0.00346	CbGpPWpGaD
Alprostadil—PTGER1—Class A/1 (Rhodopsin-like receptors)—C3—amyotrophic lateral sclerosis	0.000405	0.00346	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—SOD1—amyotrophic lateral sclerosis	0.000402	0.00343	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000399	0.00341	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—C5AR1—amyotrophic lateral sclerosis	0.000399	0.00341	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000393	0.00336	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CHMP2B—amyotrophic lateral sclerosis	0.000384	0.00328	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—DAO—amyotrophic lateral sclerosis	0.000383	0.00327	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000383	0.00327	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000373	0.00318	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000362	0.0031	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—C5AR1—amyotrophic lateral sclerosis	0.000362	0.0031	CbGpPWpGaD
Alprostadil—ABCC4—Platelet degranulation—VEGFA—amyotrophic lateral sclerosis	0.000361	0.00308	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000361	0.00308	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—PLA2G4A—amyotrophic lateral sclerosis	0.000361	0.00308	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—SOD1—amyotrophic lateral sclerosis	0.000348	0.00297	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PLB1—amyotrophic lateral sclerosis	0.000347	0.00296	CbGpPWpGaD
Alprostadil—ABCC4—Response to elevated platelet cytosolic Ca2+—VEGFA—amyotrophic lateral sclerosis	0.000344	0.00294	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000326	0.00278	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000326	0.00278	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000321	0.00274	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000317	0.00271	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	0.000312	0.00266	CbGpPWpGaD
Alprostadil—ABCC5—Disease—VCP—amyotrophic lateral sclerosis	0.000309	0.00264	CbGpPWpGaD
Alprostadil—PTGER1—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000308	0.00263	CbGpPWpGaD
Alprostadil—PTGIR—GPCR ligand binding—C3—amyotrophic lateral sclerosis	0.000308	0.00263	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000291	0.00248	CbGpPWpGaD
Alprostadil—ABCC4—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	0.00029	0.00248	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000283	0.00241	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PLB1—amyotrophic lateral sclerosis	0.000283	0.00241	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GSR—amyotrophic lateral sclerosis	0.000268	0.00229	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000266	0.00227	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—RTN4—amyotrophic lateral sclerosis	0.000266	0.00227	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000265	0.00226	CbGpPWpGaD
Alprostadil—PTGER2—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000258	0.0022	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000252	0.00215	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—VCP—amyotrophic lateral sclerosis	0.000252	0.00215	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—IGF1—amyotrophic lateral sclerosis	0.000245	0.00209	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000244	0.00208	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PFN1—amyotrophic lateral sclerosis	0.000244	0.00208	CbGpPWpGaD
Alprostadil—PTGER2—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000234	0.002	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CST3—amyotrophic lateral sclerosis	0.000222	0.0019	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—CHAT—amyotrophic lateral sclerosis	0.00022	0.00188	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000218	0.00186	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000217	0.00185	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—GFAP—amyotrophic lateral sclerosis	0.000217	0.00185	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000214	0.00183	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—C5AR1—amyotrophic lateral sclerosis	0.000214	0.00183	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—IGF1—amyotrophic lateral sclerosis	0.000212	0.00181	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—SOD1—amyotrophic lateral sclerosis	0.000207	0.00177	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000204	0.00174	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000195	0.00166	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—PLA2G4A—amyotrophic lateral sclerosis	0.000186	0.00159	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000179	0.00153	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—PLA2G4A—amyotrophic lateral sclerosis	0.000179	0.00153	CbGpPWpGaD
Alprostadil—PTGER1—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000174	0.00149	CbGpPWpGaD
Alprostadil—PTGIR—GPCR downstream signaling—C3—amyotrophic lateral sclerosis	0.000174	0.00149	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000167	0.00142	CbGpPWpGaD
Alprostadil—ABCC5—Disease—CASP9—amyotrophic lateral sclerosis	0.000161	0.00138	CbGpPWpGaD
Alprostadil—ABCC4—Platelet activation, signaling and aggregation—VEGFA—amyotrophic lateral sclerosis	0.00016	0.00137	CbGpPWpGaD
Alprostadil—PTGER1—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000158	0.00135	CbGpPWpGaD
Alprostadil—PTGIR—Signaling by GPCR—C3—amyotrophic lateral sclerosis	0.000158	0.00135	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	0.000157	0.00134	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000147	0.00126	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—SQSTM1—amyotrophic lateral sclerosis	0.000147	0.00126	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—VEGFA—amyotrophic lateral sclerosis	0.000139	0.00118	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—C3—amyotrophic lateral sclerosis	0.000138	0.00118	CbGpPWpGaD
Alprostadil—ABCC5—Disease—ERBB4—amyotrophic lateral sclerosis	0.000138	0.00118	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000138	0.00118	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ATF1—amyotrophic lateral sclerosis	0.000138	0.00118	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000131	0.00112	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CASP9—amyotrophic lateral sclerosis	0.000131	0.00112	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—APOE—amyotrophic lateral sclerosis	0.000129	0.0011	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—IGF1—amyotrophic lateral sclerosis	0.000126	0.00108	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—GSTP1—amyotrophic lateral sclerosis	0.000118	0.00101	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000112	0.00096	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—ERBB4—amyotrophic lateral sclerosis	0.000112	0.00096	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	0.000109	0.000929	CbGpPWpGaD
Alprostadil—ABCC5—Disease—APOE—amyotrophic lateral sclerosis	0.000107	0.000912	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	0.000106	0.000909	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	0.000106	0.000903	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—PLA2G4A—amyotrophic lateral sclerosis	0.000106	0.000903	CbGpPWpGaD
Alprostadil—PTGIR—Hemostasis—TP53—amyotrophic lateral sclerosis	0.000105	0.000894	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—C3—amyotrophic lateral sclerosis	9.35e-05	0.000798	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—C3—amyotrophic lateral sclerosis	9.35e-05	0.000798	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—APOE—amyotrophic lateral sclerosis	8.95e-05	0.000764	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—APOE—amyotrophic lateral sclerosis	8.7e-05	0.000743	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—APOE—amyotrophic lateral sclerosis	8.7e-05	0.000743	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—VEGFA—amyotrophic lateral sclerosis	8.26e-05	0.000705	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	8.19e-05	0.0007	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	7.74e-05	0.000661	CbGpPWpGaD
Alprostadil—ABCC5—Disease—PTGS2—amyotrophic lateral sclerosis	7.32e-05	0.000625	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	7.19e-05	0.000614	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—IGF1—amyotrophic lateral sclerosis	7.19e-05	0.000614	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	6.95e-05	0.000594	CbGpPWpGaD
Alprostadil—ABCC4—Hemostasis—TP53—amyotrophic lateral sclerosis	6.24e-05	0.000533	CbGpPWpGaD
Alprostadil—ABCC5—Metabolism—PTGS2—amyotrophic lateral sclerosis	6.13e-05	0.000524	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.53e-05	0.000473	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—CASP3—amyotrophic lateral sclerosis	5.53e-05	0.000473	CbGpPWpGaD
Alprostadil—PTGER2—Signaling Pathways—TP53—amyotrophic lateral sclerosis	5.25e-05	0.000449	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.23e-05	0.000447	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—MMP9—amyotrophic lateral sclerosis	5.23e-05	0.000447	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.7e-05	0.000401	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—VEGFA—amyotrophic lateral sclerosis	4.7e-05	0.000401	CbGpPWpGaD
Alprostadil—PTGER1—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.55e-05	0.000303	CbGpPWpGaD
Alprostadil—PTGIR—Signaling Pathways—TP53—amyotrophic lateral sclerosis	3.55e-05	0.000303	CbGpPWpGaD
